Cellectis Files 6-K, Incorporates Exhibits
Ticker: CLLS · Form: 6-K · Filed: Nov 4, 2024 · CIK: 1627281
Sentiment: neutral
Topics: sec-filing, registration-statement, administrative
TL;DR
Cellectis filed a 6-K, incorporating exhibits into its F-3 and S-8 filings. Standard procedure.
AI Summary
Cellectis S.A. filed a Form 6-K on November 4, 2024, reporting information for its registration statements. The filing incorporates by reference Exhibit 99.1 into its existing Form F-3 and Form S-8 registration statements. This action is standard procedure for companies to update or provide ongoing information to the SEC.
Why It Matters
This filing is a routine update that incorporates previous disclosures into ongoing registration statements, providing transparency for investors regarding the company's filings.
Risk Assessment
Risk Level: low — This is a routine administrative filing that incorporates previously disclosed information, posing no new immediate risks.
Key Players & Entities
- Cellectis S.A. (company) — Registrant
- November 4, 2024 (date) — Filing Date
- Form 6-K (document) — Filing Type
- Form F-3 (document) — Incorporated Registration Statement
- Form S-8 (document) — Incorporated Registration Statement
FAQ
What is the purpose of this Form 6-K filing by Cellectis S.A.?
The purpose of this Form 6-K is to report information and incorporate by reference Exhibit 99.1 into Cellectis S.A.'s existing registration statements on Form F-3 and Form S-8.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed with the SEC on November 4, 2024.
Which registration statements are being updated by this filing?
This filing incorporates information into Cellectis S.A.'s registration statements on Form F-3 (No. 333-265826) and Form S-8 (multiple numbers listed).
What type of company is Cellectis S.A. according to the filing?
Cellectis S.A. is classified under the Standard Industrial Classification code 2836, which pertains to Biological Products (no diagnostic substances).
Where is Cellectis S.A. headquartered?
Cellectis S.A. is headquartered in Paris, France, with its principal executive office located at 8, rue de la Croix Jarry, 75013 Paris.
Filing Stats: 216 words · 1 min read · ~1 pages · Grade level 8.3 · Accepted 2024-11-04 16:30:04
Filing Documents
- clls_6-k_q3_2024.htm (6-K) — 25KB
- clls-ex99_1.htm (EX-99.1) — 2462KB
- 0000950170-24-120748.txt ( ) — 2488KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CELLECTIS S.A. (Registrant) November 4, 2024 By: /s/ André Choulika André Choulika Chief Executive Officer